EIK1001

EIK1001 is an investigational agent whose form is not stated in the registry developed by Eikon Therapeutics. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06697301 (Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma) and NCT07365319 (A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer), in melanoma and non-small-cell lung cancer. The largest, NCT07365319, plans to enrol 750 participants with primary completion expected 2035-12-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.